Business context and reporting period
Filing identity: The request metadata names HYPERION DEFI, INC., but the supplied Form 10-Q is for Eyenovia, Inc. Investors should confirm the intended company. This filing covers the quarter ended September 30, 2018, and the nine months then ended.
Eyenovia is a clinical-stage biopharmaceutical company developing ophthalmology products using its Optejet micro-dosing technology. It has not generated product revenue or completed development of a product candidate.
Financial performance and condition
- Revenue: None reported; the company said it did not expect product-sale revenue in the near future.
- Net loss: $4.32 million for Q3 2018, versus $0.88 million in Q3 2017; $11.07 million for the first nine months of 2018, versus $2.97 million in the comparable 2017 period.
- Operating expenses: Q3 research and development was $2.49 million and general and administrative expense was $1.83 million. Nine-month amounts were $6.99 million and $4.08 million, respectively. No operating margin is meaningful given the absence of revenue.
- Cash flow: Nine-month operating cash use was $9.01 million, compared with $2.74 million in 2017. Financing provided $24.80 million, primarily from the January 2018 IPO. Investing cash flow was zero.
- Liquidity: Cash was $21.04 million at September 30, 2018, versus $5.25 million at December 31, 2017. Working capital was $19.6 million; accumulated deficit was $30.3 million.
- Debt and liabilities: No debt was outstanding. Total liabilities were $1.73 million, including $1.73 million of current liabilities.
- Equity and dilution: Stockholders’ equity was $19.74 million. Common shares outstanding were 10,088,996 at September 30, 2018; 2.23 million options were outstanding.
Changes versus the prior comparable period
- Q3 operating expenses rose to $4.32 million from $0.89 million; nine-month expenses rose to $11.07 million from $2.97 million. Management attributed the increases to expanded clinical and development activity, hiring, professional fees, public-company costs, and stock-based compensation.
- Cash increased following the IPO. The filing reports IPO net proceeds of approximately $24.5 million in the notes and offering discussion, while MD&A states $24.7 million; the cash-flow statement reports $25.09 million of IPO proceeds before certain issuance-cost payments.
- All outstanding preferred stock converted into common stock immediately before the IPO. The company also entered a new New York office lease in August 2018, with approximately $1.29 million of total base-rent commitments through September 2023.
Outlook, risks and unusual items
- Management expected cash on hand to fund operating and capital requirements for at least 12 months from issuance of the financial statements, but anticipated needing additional capital thereafter. Failure to raise funds could require reduced spending or curtailed R&D.
- Management expected R&D and G&A expenses to increase. It planned to begin MicroStat Phase III trials in November 2018 and MicroProst Phase III trials in the first half of 2019, subject to regulatory steps and feedback; MicroTears was expected to proceed with registration activities without Phase III trials.
- A Corinthian-related shareholder lawsuit was settled on October 29, 2018 for $600,000. Eyenovia agreed to contribute $150,000, accrued at September 30; the remaining $450,000 was paid by Corinthian’s insurer. Eyenovia reported that its contribution was paid after quarter-end.
- Disclosure controls and procedures were deemed ineffective as of September 30, 2018. The filing identifies continuing material weaknesses involving segregation of duties, related-party identification, communication of agreement terms to the board, and R&D expense recording. Remediation steps had been taken, but management said effectiveness could not yet be assured.
- Related-party arrangements include consulting, office leases, R&D contractor services, and a license arrangement with Senju, which is connected to a director’s family. The company reported no Senju royalties earned because there had been no commercial sales in Asia.
- Cash deposits exceeding FDIC insurance limits totaled $20.79 million. The company reported no material off-balance-sheet arrangements.
Most important facts to verify
- Whether the intended filing is Eyenovia, Inc., rather than the company named in the request metadata.
- The IPO net-proceeds figure: the filing cites approximately $24.5 million in some sections and $24.7 million in MD&A.
- Actual cash burn, clinical-trial timing and costs, and whether additional financing will be required after the stated 12-month runway.
- Completion and effectiveness of remediation for the disclosed internal-control material weaknesses.
- Settlement payment and remaining obligations, along with the terms and governance oversight of related-party transactions.